A) Preventing all transmission B) Eradicating the virus globally C) Reducing mutation rates of the virus D) Preventing symptomatic, often severe, illness
A) Janssen B) Razi Cov Pars C) Pfizer–BioNTech D) Soberana
A) Nucleocapsid protein B) Envelope protein C) Membrane protein D) Spike protein
A) They completely block viral entry B) They are easier to manufacture C) They have no genomic variability D) They induce a robust T-cell response
A) Locking the spike protein into its prefusion configuration B) Preventing lipid degradation C) Creating a live attenuated virus D) Increasing the speed of mRNA production
A) Mixed with attenuated live virus B) Injected directly into cell nuclei C) Encapsulated in lipid nanoparticles D) Attached to viral vectors
A) CVnCoV B) Comirnaty C) Mnexspike D) Spikevax
A) Lipid nanoparticles B) The preservative agents C) The mRNA strands D) The nucleoside modifications
A) Mnexspike B) Convidecia C) Comirnaty D) Spikevax
A) Twelve B) Exactly three C) At least nine D) Only two
A) August 2020 B) January 2021 C) March 2020 D) December 2019
A) The World Health Organization B) Katalin Karikó and Drew Weissman C) Pfizer and BioNTech D) Moderna and Novavax
A) It wanes B) It disappears immediately C) It becomes permanent D) It increases
A) Only with medical supervision B) No C) Yes D) Only after weaning
A) 20 to 25 million B) 1 to 3 million C) 14.4 to 19.8 million D) 5 to 10 million
A) Permanent paralysis B) Autoimmune disease C) Chronic organ failure D) Myalgia
A) Over 50 billion B) Over 13 billion C) Exactly 10 billion D) Under 5 billion
A) Ebola research B) Zika research C) Influenza research D) SARS and MERS research
A) To cure long COVID B) To replace initial vaccines entirely C) To serve as booster doses D) To act as a treatment for infected individuals
A) The wealthiest citizens B) The elderly and healthcare workers C) Only government officials D) Children and students
A) A few months B) Several years C) Less than one year D) Over two decades
A) Equine influenza B) Feline coronavirus C) Bovine rotavirus D) Porcine circovirus
A) One was approved for SARS B) Two were approved for MERS C) Several were widely used D) None existed
A) Approved in 2005 B) None exists C) Approved in 2020 D) Approved in 2006
A) Five B) One C) Zero D) Three
A) Inactive virus B) mRNA-based C) DNA-based D) Live attenuated
A) Less than one year B) Six months C) More than a decade D) Two to three years
A) 2020 B) 2015 C) 2005 D) 2010
A) Influenza B) SARS C) MERS D) Ebola
A) Primates only B) Birds only C) Humans only D) Non-human animals
A) mRNA-based B) Viral-vectored C) Inactivated virus D) Protein subunit
A) Influenza virus B) Rhinovirus C) Coronavirus D) Adenovirus
A) By transferring mRNA directly to the nucleus B) By producing an antigen via encoded DNA C) By using heat-killed viral particles D) By injecting live coronavirus
A) Ad10 B) Ad2 C) Ad5 D) Ad26
A) By removing their DNA B) By heat or formaldehyde C) By freezing them in liquid nitrogen D) By coating them in protein subunits
A) CoronaVac B) Novavax C) ZF2001 D) Convidecia
A) By infecting moth cells with a modified baculovirus B) By using cultured adenovirus C) By chemical synthesis of proteins D) By heat-inactivation of SARS-CoV-2
A) Protein antigens B) RNA or DNA C) A lipid membrane D) Spike proteins
A) Covaxin B) QazVac C) Bimervax D) Sputnik V
A) 10 B) 25 C) 50 D) 100
A) Sputnik V B) Razi Cov Pars C) Pneucolin D) BCG vaccine
A) IgE B) IgG C) IgM D) IgA
A) Iran B) China C) Russia D) India
A) Intranasal spray B) Intravenous infusion C) Intramuscular injection D) Oral administration
A) 2024 B) 2022 C) 2026 D) 2025
A) Ease of administration without needles B) Requirement for fewer doses C) Faster manufacturing time D) Higher viral load suppression
A) Innate cellular immunity B) Mucosal immunity C) Passive immunity D) Systemic immunity
A) The first viral component of Sputnik V B) iNCOVACC C) Razi Cov Pars D) Pneucolin
A) USA B) China C) Iran D) India
A) March 2022 B) June 2025 C) May 2024 D) April 2022
A) China B) Canada C) France D) UK
A) Targeting the entire viral genome B) Targeting the receptor-binding domain C) Focusing on pediatric populations D) Targeting only the nasal cavity
A) Walter Reed Army Institute of Research B) Chinese Center for Disease Control C) White House D) European Medicines Agency
A) Physical distancing B) Overabundance of funding C) Governmental bans on science D) Lack of interest
A) Changing transmission rates make the virus a 'moving target' B) International borders are closed to research C) Participants prefer placebo groups D) The vaccines are too expensive
A) Vaccine Bank B) Operation Warp Speed C) R&D Blueprint D) COVAX
A) Diagnostics B) Health Systems Connector C) Manufacturing D) Therapeutics
A) Regulating drug safety laws B) Developing medical school curricula C) Managing global vaccine distribution D) Funding disease-fighting technology
A) The Vaccine Bank B) Operation Warp Speed C) The R&D Blueprint D) ACT-Accelerator
A) Novavax B) Moderna C) Johnson & Johnson D) Pfizer
A) Severe infections B) Environmental surfaces C) Asymptomatic carriers only D) Mild infections
A) Around 95% B) Around 77% C) Around 50% D) Around 26%
A) 50% B) 90% C) 26% D) 77%
A) Boosters B) Placebos C) Therapeutics D) Wait times
A) World Health Organization B) Red Cross C) United Nations D) Doctors Without Borders
A) Individual protection titers are clearly defined B) Individual protection titers are determined by weight C) Individual protection titers are not associated with immunity D) Individual protection titers remain unknown
A) Every month B) Every two years C) Every six months D) Once per lifetime
A) 70% B) 19% C) 90% D) 43%
A) Randomized clinical trials B) Computer simulations C) Observational studies D) Case reports only
A) Yes, but only in the Moderna trials B) Yes, but only in the Pfizer trials C) Yes, in all of them D) No
A) Single-dose regimen B) Homologous vaccination C) Standard regimen D) Heterologous vaccination
A) The risks from COVID-19 are far higher. B) The risks are about the same. C) The risks from the vaccine are higher. D) There is no way to compare the risks.
A) Inflammation. B) Allergic reaction. C) Intramuscular trauma. D) Nocebo effect.
A) 250. B) 2,700. C) 17. D) 55.
A) People with chronic illness only. B) Older people. C) Infants. D) Younger people.
A) 16%. B) 11.6%. C) 20%. D) 5%.
A) One week. B) Two menstrual cycles. C) Six months. D) One year.
A) Inactivated vaccines. B) DNA vaccines. C) Vector vaccines. D) mRNA vaccines.
A) 9. B) 31. C) 250. D) 73.
A) 0.5% B) 1.07% C) 0.015% D) 5%
A) Young males B) Immunocompromised individuals C) Children under 5 D) Elderly females
A) CoWIN B) VigiBase C) EudraVigilance D) Aarogya Setu
A) Remains neutral on the issue B) Supports stricter patent enforcement C) Supports waiving intellectual property protections D) Proposed a ban on foreign vaccine exports
A) Countries with no vaccine supply. B) Poor countries. C) Countries with low tourism rates. D) Rich countries.
A) Countries in the northern hemisphere. B) Island nations. C) Poor countries. D) Rich countries.
A) There was no interest in getting vaccinated. B) Supply significantly exceeded demand. C) Vaccines were readily available for everyone. D) Demand significantly exceeded supply.
A) A group of pharmacy owners. B) The state health department. C) High school students only. D) Mukesh Aggarwal.
A) @VaccineHunter B) @BayVaccine C) @CovaxSF D) @CVSBot
A) MyTurn. B) HealthPortal. C) VaccineAlert. D) GlobalVaccineTracker.
A) The websites were hacked by competitors B) The developers lost interest C) They were banned by federal law D) The need for intensive monitoring declined
A) Open-source scripts B) Telephone hotlines C) Physical paper maps D) Official government apps
A) Florida B) California C) New York D) Texas
A) Joe Biden B) Ron DeSantis C) Alex Azar D) Donald Trump
A) Willful misconduct B) High pricing C) Product spoilage D) Negligence
A) United Kingdom B) Argentina C) Brazil D) France
A) Conditional marketing authorization B) Liability exemption C) Standard authorization D) Emergency use permit
A) September 2022 B) December 2020 C) November 2023 D) February 2020
A) A congressional hearing B) A grand jury C) A Supreme Court trial D) An international tribunal
A) Public Health Emergency Act B) Consumer Vaccine Safety Act C) PREP Act D) Texas Deceptive Trade Practices Act
A) Philippines B) Saudi Arabia C) United States D) China |